Clinical trial
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate…
NCT00036556 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00036556 |
|---|---|
| Title | Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer |
| Official title | A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | Atrasentan |
| Enrollment | 941 |
| Start date | Jun 1, 2001 |
| First posted | May 13, 2002 |
| Last update posted | Aug 15, 2007 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Italy, Netherlands, New Zealand, Poland and 5 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: